6.11
3.48%
-0.22
시간 외 거래:
6.11
전일 마감가:
$6.33
열려 있는:
$6.37
하루 거래량:
631.91K
Relative Volume:
0.65
시가총액:
$453.63M
수익:
-
순이익/손실:
$-96.66M
주가수익비율:
-2.8419
EPS:
-2.15
순현금흐름:
$-83.73M
1주 성능:
+2.69%
1개월 성능:
+4.80%
6개월 성능:
-62.19%
1년 성능:
-53.14%
올레마 Stock (OLMA) Company Profile
명칭
Olema Pharmaceuticals Inc
전화
(415) 651-3316
주소
780 BRANNAN STREET, SAN FRANCISCO
OLMA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
6.11 | 453.63M | 0 | -96.66M | -83.73M | -2.15 |
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
올레마 Stock (OLMA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-04-02 | 개시 | Goldman | Buy |
2024-01-30 | 개시 | Citigroup | Buy |
2023-07-21 | 개시 | Oppenheimer | Outperform |
2023-05-05 | 개시 | CapitalOne | Overweight |
2023-02-22 | 개시 | Credit Suisse | Outperform |
2022-07-06 | 재개 | Canaccord Genuity | Buy |
2022-06-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2022-02-28 | 개시 | H.C. Wainwright | Neutral |
2021-12-07 | 재개 | Cowen | Outperform |
2020-12-14 | 개시 | Canaccord Genuity | Buy |
2020-12-14 | 개시 | Cowen | Outperform |
2020-12-14 | 개시 | JP Morgan | Overweight |
2020-12-14 | 개시 | Jefferies | Buy |
모두보기
올레마 주식(OLMA)의 최신 뉴스
HR Positive/ HER2 Negative Breast Cancer Pipeline 2024: MOA - openPR
How To Trade (OLMA) - Stock Traders Daily
JPMorgan Chase & Co. Buys 157,171 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
JPMorgan Chase & Co. Purchases 157,171 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock Holdings Increased by Hennion & Walsh Asset Management Inc. - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives $27.00 Consensus Target Price from Brokerages - MarketBeat
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Form 424B5 Olema Pharmaceuticals, - StreetInsider.com
Barclays PLC Purchases 48,614 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Bain Capital Life Sciences Investors, LLC Acquires Significant S - GuruFocus.com
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Major Shareholder Acquires $1,728,000.00 in Stock - MarketBeat
Bain Capital Life Sciences buys $1.7m in Olema Pharmaceuticals stock - Investing.com Nigeria
Olema Pharmaceuticals announces equity security exchange By Investing.com - Investing.com Australia
Olema Pharmaceuticals announces equity security exchange - Investing.com India
Olema Pharmaceuticals stock hits 52-week low at $5.02 - Investing.com India
Olema Pharmaceuticals stock hits 52-week low at $5.02 By Investing.com - Investing.com South Africa
(OLMA) Investment Report - Stock Traders Daily
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Olema Pharmaceuticals Awards New Employee Stock Options for Cancer Drug Development Team - StockTitan
Olema Pharmaceuticals stock hits 52-week low at $5.55 By Investing.com - Investing.com Australia
Olema Pharmaceuticals stock hits 52-week low at $5.55 - Investing.com India
Olema Oncology to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Geode Capital Management LLC Decreases Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Geode Capital Management LLC Sells 125,170 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Barclays PLC Acquires 48,614 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Oncology Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateForm 8-K - Marketscreener.com
Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion - MSN
State Street Corp Boosts Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Rating of “Buy” by Brokerages - Defense World
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Rating of "Buy" by Brokerages - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 7,616 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $4,730,136.75 in Stock - MarketBeat
Olema Pharmaceuticals director Graham Walmsley sells $4.73m in stock By Investing.com - Investing.com South Africa
Olema Pharmaceuticals director Graham Walmsley sells $4.73m in stock - Investing.com
(OLMA) Technical Pivots with Risk Controls - Stock Traders Daily
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Bought by Wellington Management Group LLP - MarketBeat
Charles Schwab Investment Management Inc. Increases Stock Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - MarketBeat
Charles Schwab Investment Management Inc. Buys 207,565 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) - Defense World
What is HC Wainwright’s Forecast for OLMA FY2024 Earnings? - Defense World
What is HC Wainwright's Estimate for OLMA FY2024 Earnings? - MarketBeat
Olema Pharmaceuticals stock hits 52-week low at $7.67 By Investing.com - Investing.com Canada
Olema Pharmaceuticals stock hits 52-week low at $7.67 - Investing.com India
Olema Pharmaceuticals CEO Sean Bohen sells shares worth $986,365 By Investing.com - Investing.com Nigeria
Olema Pharmaceuticals, Inc. announced that it has received $249.999225 million in funding from a group of investors - Marketscreener.com
올레마 (OLMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):